PRA consolidates in Poland to support growth, contain costs

By Nick Taylor

- Last updated on GMT

Related tags: Clinical trial, Food and drug administration, Europe

PRA has relocated its Poland-based early development services and product registration teams into a larger shared office after achieving “solid increases in the placement of clinical studies”.

Consolidating both teams in the same larger, more modern office in Warsaw, Poland will accommodate continuing growth, improve internal and external communications and support “cost containment for shared services​”.

PRA Phase I to IV trials in Poland are “achieving high patient recruitment and accessing excellent quality data​”, Susan Stansfield, executive vice president (EVP), product registration, Europe, Africa and Asia-Pacific, told Outsourcing-Pharma.

Solid increases in the placement of clinical studies​” have been achieved, said Stansfield, with PRA experiencing “growth rates ahead of the market​”. PRA “fully expects​” growth in Poland to continue, citing European Medicines Agency (EMA) data​ as evidence of the market’s strength.


In Poland PRA provides feasibility, site start-up, site management and monitoring of Phase I to IV clinical trials. This is supported by medical affairs, project management and quality assurance services.

Special patient groups are accessed for specific Phase I needs. This is handled by the early development services team who establish Phase I study environments within central medical facilities that specialise in treating target patient populations.

Future expansion

Geographic expansion at PRA is underpinned by a patient-driven medical informatics technology. Using the system PRA can “estimate potential patient access that would result from moving into new territories and expanding in existing ones​”, said Stansfield.

We expect to see further growth in Eastern Europe, Middle East and Africa, Asia and Latin America​”, said Stansfield, and PRA is “growing and consolidating in these regions, opening new facilities to house our staff as appropriate​”.

Related news

Show more

Related products

show more

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

What the Best Clinical Study Build Pros Do

What the Best Clinical Study Build Pros Do

Formedix | 09-May-2022 | Technical / White Paper

Getting your clinical study designed and built ready for data collection takes A LOT of work and expertise… you've got to do all your CRF designs;...

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 18-Apr-2022 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Related suppliers

Follow us


View more